GLGabriel André Pedral Diniz Leite

Gabriel André Pedral Diniz Leite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriel André Pedral Diniz Leite has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Meta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

    by Igor Boechat Silveira, Leonardo Corrêa Süffert, Gustavo André Pedral Diniz Leite, Milena Ramos Tomé, Sarah Quick Lourenço de Lima, Gabriel André Pedral Diniz Leite, Bernardo de Faria Moraes, Pedro Robson Costa Passos, Guilherme Grossi Lopes Cançado

    Background/Aims: Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial‐level moderators in randomized controlled trials of contemporary therapies. Methods: We performed a systematic review and meta‐analysis of placebo‐controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst–Itch NRS (WI‐NRS) scores. Secondary outcomes included PBC‐40 and 5‐D Itch scores. We used random‐effects models with Hartung–Knapp adjustment and meta‐regression. Results: Thirteen trials ( n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow‐up periods of up to 52 weeks. The pooled SMC was −0.49 (95% CI, −0.72 to −0.27) overall, and −0.57 (95% CI, −0.81 to −0.33) for moderate‐to‐severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate‐to‐severe). In moderate‐to‐severe patients, NRS showed a significant mean reduction of −1.62, whereas the WI‐NRS change (−0.65) was not statistically significant. Significant reductions occurred in the PBC‐40 itch domain (−2.02) and overall score (−9.13), while 5‐D Itch changes were non‐significant. None of the evaluated moderators were statistically significant. Conclusions: The magnitude of placebo‐associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic‐pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. Trial Registration: PROSPERO registration number: CRD420261385974

  • Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply

    by Bernardo de Faria Moraes, Igor Boechat Silveira, Gabriel André Pedral Diniz Leite, Maria Luisa Motta Fonseca, Leonardo Corrêa Suffert, Luisa Medeiros Visentini, Luis Pedro Possapp Beis, Guilherme Grossi Lopes Cançado

  • Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis—Authors' Reply

    by Bernardo de Faria Moraes, Igor Boechat Silveira, Gabriel André Pedral Diniz Leite, Maria Luisa Motta Fonseca, Leonardo Corrêa Suffert, Luisa Medeiros Visentini, Luis Pedro Possapp Beis, Guilherme Grossi Lopes Cançado

  • Top Cited Papers
    Open Access

    Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis

    by Bernardo de Faria Moraes, Gustavo André Pedral Diniz Leite, Igor Boechat Silveira, Gabriel André Pedral Diniz Leite, Maria Luisa Motta Fonseca, Leonardo Corrêa Suffert, Luisa Medeiros Visentini, Luis Pedro Possapp Beis, Guilherme Grossi Lopes Cançado

    Background: The role of statins in cirrhosis remains controversial. Historically restricted due to safety concerns, emerging evidence highlights potential pleiotropic benefits, though effects on mortality and decompensation remain uncertain. Aims: To evaluate the effects of statin therapy on all‐cause mortality, hepatic decompensation, hepatic venous pressure gradient (HVPG), and hepatocellular carcinoma (HCC) in cirrhosis. Methods: We systematically searched major databases until July 2025 for randomised controlled trials (RCTs) and observational studies comparing statin therapy versus non‐use in cirrhosis. Random‐effects meta‐analyses were performed. Results: The meta‐analysis included 25 studies (9 RCTs, 16 observational) with 81,992 patients. Statins reduced all‐cause mortality in the overall analysis (unadjusted odds ratio 0.59; 95% CI: 0.48–0.71) and in RCTs (odds ratio 0.45; 95% CI 0.25–0.82), supported by a significant HVPG reduction. Conversely, statins reduced hepatic decompensation in the overall analysis (unadjusted odds ratio 0.56; 95% CI: 0.47–0.66) but not in RCTs (odds ratio 0.75; 95% CI: 0.52–1.09). Observational data indicated a protective association for HCC (adjusted hazard ratio 0.61; 95% CI: 0.46–0.82), and no RCT reported this outcome. Conclusions: Statin therapy is associated with improved survival in cirrhosis, supported mechanistically by reductions in portal pressure. Observational evidence suggests benefits for decompensation and HCC, though these remain uncertain due to residual confounding. Large‐scale, long‐term RCTs are needed to clarify the role of statins as disease‐modifying therapy in cirrhosis.


  • Re-Evaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients: A Systematic Review and Meta-Analysis

    by Bernardo de Faria Moraes, Gabriel André Pedral Diniz Leite, Gustavo André Pedral Diniz Leite, Maria Luisa Motta Fonseca, Rodolfo Augusto Assis Rezende, Guilherme Grossi Lopes Cançado

    INTRODUCTION: The benefit of proton pump inhibitors (PPIs) in improving outcomes after endoscopic band ligation (EBL) of esophageal varices in cirrhosis remains uncertain. We aimed to evaluate whether PPI use reduces bleeding and mortality after EBL compared with nonuse. METHODS: Major databases were systematically searched until January 2025. Randomized clinical trials (RCTs) and observational studies comparing PPI use vs nonuse after EBL of esophageal varices in patients with cirrhosis were included. Random-effects meta-analyses were conducted using restricted maximum likelihood estimation. Risk ratios (RR), odds ratios (ORs), or standardized mean differences with 95% confidence intervals (CIs) were calculated for outcomes. RESULTS: Eleven studies (4 RCTs and 7 observational) comprising 7,459 patients with cirrhosis undergoing EBL were included. In pooled unadjusted analyses, PPI use was associated with reduced post-EBL bleeding (OR 0.76; 95% CI 0.62–0.92; I 2 = 29.6%) and all-cause mortality (OR 0.48; 95% CI 0.24–0.97; I 2 = 0.0%). More rigorous analyses showed no benefit: adjusted observational data for post-EBL bleeding and RCT data for post-EBL bleeding and all-cause mortality were not significant ( P > 0.05). Similarly, for the mechanistic outcome of post-EBL ulcer bleeding, RCT data showed no statistically significant effect (RR 0.54; 95% CI 0.25–1.16; I 2 = 0.0%). Trial sequential analysis confirmed the cumulative RCT evidence for bleeding is underpowered. DISCUSSION: Current evidence is insufficient to support routine PPI use after EBL. RCT data remain underpowered and inconclusive, emphasizing the need for adequately powered trials.